Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 3 studies | 23% ± 3% |
Insufficient scRNA-seq data for expression of CCN3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 94% | 3236.28 | 616 / 653 | 84% | 15.97 | 511 / 605 |
adrenal gland | 100% | 65105.26 | 258 / 258 | 69% | 254.27 | 158 / 230 |
prostate | 52% | 1023.21 | 127 / 245 | 96% | 49.26 | 483 / 502 |
skin | 56% | 975.04 | 1020 / 1809 | 82% | 114.43 | 389 / 472 |
kidney | 30% | 529.44 | 27 / 89 | 89% | 33.01 | 805 / 901 |
breast | 53% | 844.68 | 242 / 459 | 61% | 10.43 | 680 / 1118 |
blood vessel | 100% | 43128.15 | 1333 / 1335 | 0% | 0 | 0 / 0 |
ovary | 9% | 190.98 | 17 / 180 | 87% | 24.65 | 373 / 430 |
lung | 36% | 609.66 | 208 / 578 | 55% | 7.59 | 630 / 1155 |
pancreas | 5% | 46.42 | 16 / 328 | 85% | 17.85 | 152 / 178 |
uterus | 37% | 594.89 | 63 / 170 | 49% | 12.94 | 224 / 459 |
brain | 26% | 380.54 | 684 / 2642 | 59% | 9.33 | 414 / 705 |
esophagus | 13% | 152.02 | 182 / 1445 | 61% | 9.19 | 112 / 183 |
intestine | 33% | 525.80 | 323 / 966 | 39% | 5.54 | 204 / 527 |
tonsil | 0% | 0 | 0 / 0 | 62% | 13.46 | 28 / 45 |
adipose | 60% | 1402.82 | 721 / 1204 | 0% | 0 | 0 / 0 |
stomach | 13% | 229.41 | 48 / 359 | 38% | 6.43 | 108 / 286 |
eye | 0% | 0 | 0 / 0 | 39% | 5.56 | 31 / 80 |
bladder | 5% | 34.57 | 1 / 21 | 31% | 4.34 | 157 / 504 |
heart | 33% | 560.14 | 283 / 861 | 0% | 0 | 0 / 0 |
liver | 0% | 12.14 | 1 / 226 | 19% | 2.66 | 78 / 406 |
muscle | 6% | 92.10 | 47 / 803 | 0% | 0 | 0 / 0 |
spleen | 2% | 41.74 | 6 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 6.51 | 7 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0048659 | Biological process | smooth muscle cell proliferation |
GO_0001525 | Biological process | angiogenesis |
GO_0010468 | Biological process | regulation of gene expression |
GO_0014909 | Biological process | smooth muscle cell migration |
GO_0033627 | Biological process | cell adhesion mediated by integrin |
GO_0060392 | Biological process | negative regulation of SMAD protein signal transduction |
GO_1904057 | Biological process | negative regulation of sensory perception of pain |
GO_0007165 | Biological process | signal transduction |
GO_0010761 | Biological process | fibroblast migration |
GO_0002062 | Biological process | chondrocyte differentiation |
GO_0007155 | Biological process | cell adhesion |
GO_0046676 | Biological process | negative regulation of insulin secretion |
GO_0061484 | Biological process | hematopoietic stem cell homeostasis |
GO_0035767 | Biological process | endothelial cell chemotaxis |
GO_1901223 | Biological process | negative regulation of non-canonical NF-kappaB signal transduction |
GO_0010832 | Biological process | negative regulation of myotube differentiation |
GO_0071603 | Biological process | endothelial cell-cell adhesion |
GO_1990523 | Biological process | bone regeneration |
GO_0045597 | Biological process | positive regulation of cell differentiation |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_1902731 | Biological process | negative regulation of chondrocyte proliferation |
GO_0045747 | Biological process | positive regulation of Notch signaling pathway |
GO_0044342 | Biological process | type B pancreatic cell proliferation |
GO_0090027 | Biological process | negative regulation of monocyte chemotaxis |
GO_0060326 | Biological process | cell chemotaxis |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0043025 | Cellular component | neuronal cell body |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0031012 | Cellular component | extracellular matrix |
GO_0030425 | Cellular component | dendrite |
GO_0005737 | Cellular component | cytoplasm |
GO_0005921 | Cellular component | gap junction |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0030424 | Cellular component | axon |
GO_0008201 | Molecular function | heparin binding |
GO_0005112 | Molecular function | Notch binding |
GO_0008083 | Molecular function | growth factor activity |
GO_0005178 | Molecular function | integrin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CCN3 |
Protein name | CCN family member 3 (Cellular communication network factor 3) (Insulin-like growth factor-binding protein 9) (IBP-9) (IGF-binding protein 9) (IGFBP-9) (Nephro blastoma-overexpressed gene protein homolog) (Protein NOV homolog) (NovH) CCN3 |
Synonyms | NOVH NOV IGFBP9 |
Description | FUNCTION: Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival . Acts by binding to integrins or membrane receptors such as NOTCH1 . Essential regulator of hematopoietic stem and progenitor cell function . Inhibits myogenic differentiation through the activation of Notch-signaling pathway . Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling . Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival . Also plays a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts . Involved in bone regeneration as a negative regulator (By similarity). Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification . Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion (By similarity). Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway . Contributes to the control and coordination of inflammatory processes in atherosclerosis (By similarity). Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement . . |
Accessions | B3FHX2 P48745 ENST00000259526.4 |